Immunotherapy for renal cell cancer in the era of targeted therapy

Expert Review of Anticancer Therapy

Volumn 8, Issue 6, 2008, Pages 907-919

  Coppin, Chris ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Immunotherapy; Outcomes; Renal cell cancer

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; CANCER VACCINE; CARBONATE DEHYDRATASE IX; CIMETIDINE; COUMARIN; CYCLOOXYGENASE 2 INHIBITOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FLUOROURACIL; GAMMA INTERFERON; INTERFERON; INTERLEUKIN 2; MEDROXYPROGESTERONE ACETATE; ONCOPHAGE; PLACEBO; RECOMBINANT ALPHA INTERFERON; RECOMBINANT INTERLEUKIN 2; RENIALE; RETINOIC ACID; SORAFENIB; STAT1 PROTEIN; STAT3 PROTEIN; SUNITINIB; TAMOXIFEN; TEMSIROLIMUS; THALIDOMIDE; VINBLASTINE; VON HIPPEL LINDAU PROTEIN; ANTINEOPLASTIC AGENT; IMMUNOLOGIC FACTOR;

ANOREXIA; ANTIANGIOGENIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; CYTOREDUCTIVE SURGERY; DONOR LYMPHOCYTE INFUSION; DOSE RESPONSE; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HUMAN; IMMUNOREGULATION; KIDNEY CANCER; KIDNEY CARCINOMA; LEUKAPHERESIS; LOW DRUG DOSE; MENTAL DISEASE; MONOTHERAPY; NEPHRECTOMY; PATIENT SELECTION; PROGNOSIS; QUALITY OF LIFE; REVIEW; SURVIVAL RATE; TUMOR IMMUNITY; TUMOR SUPPRESSOR GENE; UNSPECIFIED SIDE EFFECT; DRUG DELIVERY SYSTEM; IMMUNOLOGY; IMMUNOTHERAPY; KIDNEY TUMOR; MULTIMODALITY CANCER THERAPY;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; INTERFERON-ALPHA; INTERLEUKIN-2; KIDNEY NEOPLASMS; NEPHRECTOMY; SURVIVAL RATE;

EID: 47249101223     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.8.6.907     Document Type: Review

References (130)

1. Klein G. Tumor immunology: a general appraisal. In: Scientific Foundations of Oncology. Symington T, Carter RL (Eds). Heinemann, London, UK, 497-504 (1976)
2. Currie GA. Eighty years of immunotherapy: a review of immunological methods used for the treatment of cancer. Br. J. Cancer 26, 141-145 (1972).
3. Wagstaff J. Renal cell cancer: is immunotherapy dead? Ann. Oncol. 18(Suppl. 9), 94-97 (2007),
4. Cebon J, Gedye C, John T, Davis ID. Immunotherapy of advanced or metastatic melanoma. Clin. Adv. Hem. Onc. 5, 994-1006 (2007).
5. Cohen HT, McGovern FJ. Renal-cell carcinoma. N. Engl. J. Med. 353, 2477-2490 (2005).
6. Malmberg K-J. Effective immunotherapy against cancer. Cancer Immunol. Immunother. 53, 879-892 (2004).
7. Gouttefangeas C, Stenzl A, Stevanovic S, Rammensee H-G. Immunotherapy of renal cell carcinoma. Cancer Immunol. Immunother. 56, 117-128 (2007).
8. McDermott DF, Rini BI. Immunotherapy for metastatic renal cell carcinoma. BJU Int. 99, 1282-1288 (2007).
9. Parton M, Gore M, Eisen T. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer. J. Clin. Oncol. 35, 5584-5592 (2006).
10. Immunology (7th Edition). Roitt I, Brostoff J, Male D (Eds). Mosby, PA, USA (2006).
11. Uzzo RG. The basic biology and immunobiology of renal cell carcinoma: considerations for the clinician. Urol. Clin. North Am. 30, 423-436 (2003).
12. The biology of cancer. Weinberg RA (Ed.). Garland Science, New York, USA (2007).
13. Yang JC, Childs R. Immunotherapy for renal cell cancer. J. Clin. Oncol. 35, 5576-5583 (2006).
14. Coppin C, Porzsolt F, Autenrieth M, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst. Rev. 3, CD001425 (2006).
15. Coppin C, Le L, Porzsolt F, Wilt T. Targeted therapy for advanced renal cell cancer. Cochrane Database Syst Rev. 2, CD006017 (2008).
16. Hipp MM, Hilf N, Walter S et al. Sorafenib but not sunitinib affects the induction of immune responses. J. Clin. Oncol. 25 (18 Suppl.), A3504 (2007).
17. Mancini V, Battaglia M, Ditonno P et al. Current insights in renal cell cancer pathology. Urol. Oncol. 26, 225-238 (2008).
18. Kovacs G, Akhtar M, Beckwith B et al. The Heidelberg classification of renal cell tumours. J. Path. 183, 131-133 (1997).
19. Linehan WM, Pinto PA, Srinivasan R et al. Identification of the genes for kidney cancer opportunity for disease-specific targeted therapeutics. Clin. Cancer Res. 13, 671s-679s (2007).
20. Pantuck AJ, Zeng G, Belldegrun AS, Figlin RA. Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway. Clin. Cancer Res. 9, 4641-4652 (2003).
21. Oliver RT, Nethersell AB, Bottomley JM. Unexplained spontaneous regression and α-interferon as treatment for metastatic renal carcinoma. Br J. Urol. 63, 128-131 (1989).
22. Gleave ME, Elhilali M, Fradet Y et al. Interferon γ-1b compared with placebo in metastatic renal-cell carcinoma. N. Engl. J. Med. 338, 1265-1271 (1998).
23. Gore ME, Porta C, Oudard S et al. Sunitinib in metastatic renal cell carcinoma: preliminary assessment of toxicity in an expanded access trial with subpopulation analysis. ASCO Annual Meeting Proceedings. J. Clin. Oncol. 25 (18 Suppl.), 5010 (2007).
24. Medical Research Council Renal Cancer Collaborators. Interferon-α and survival in metastatic renal carcinoma: early results of a randomized controlled trial. Lancet 353, 14-17 (1999).
25. Motzer RJ, Bacik J, Murphy BA et al. Interferon-α as a comparative treatment for clinical trials of new therapies against renal cell carcinoma. J. Clin. Oncol. 20, 289-296 (2002).
26. Mekhail TM, Abou-Jawde RM, BouMerhi G et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J. Clin. Oncol. 23, 832-841 (2005).
27. Motzer RJ, Figlin RA, Hutson TE et al. Sunitinib versus interferon-α as first-line treatment of metastatic renal cell carcinoma: updated results and analysis of prognostic factors. J. Clin. Oncol. 25(18 Suppl.), A5024 (2007).
28. Negrier S, Gomez R, Douillard JY et al. Prognostic factors of response or failure of treatment in patients with metastatic renal carcinoma treated by cytokines: a report from in the Groupe Francais d'Immunotherapie. World J. Urol. 23, 161-165 (2005).
29. Royston P, Bacik J, Elson P et al. A consensus prognostic factor model for survival in patients with metastatic renal cell carcinoma: an IKCWG study. J. Clin. Oncol. 25(18 Suppl.), A5109 (2007).
30. Motzer RJ, Bacik J, Schwartz LH et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J. Clin. Oncol. 22, 454-463 (2004).
31. Escudier B, Choueiri TK, Oudard S et al. Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large Phase III trial with shark cartilage extract AE941. J. Urol. 178, 1901-1905 (2007).
32. Motzer RJ, Bacik J, Mariani T et al. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J. Clin. Oncol. 20, 2376-2381 (2002).
33. Flanigan RC, Mickisch G, Sylvester R et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J. Urol. 171, 1071-1076 (2004).
34. Hancock B, Griffiths G, Ritchie A et al. Updated results of the MRC randomized controlled trial of α interferon vs MPA in patients with metastatic renal carcinoma. Proc. ASCO 19, A1336 (2000).
35. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon α in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115-124 (2007).
36. Choueiri TK, Rini BI, Garcia JA et al. Prognostic factors associated with long-term survival in previously untreated metastatic renal cell carcinoma. Ann. Oncol. 18, 249-255 (2007).
37. Hinz T, Buchholz CJ, van der Stappen T et al. Manufacturing and quality control of cell-based tumor vaccines: a scientific and a regulatory perspective. J. Immunother. 29, 472-476 (2006).
38. Zia MI, Siu LL, Pond GR, Chen EX. Comparison of outcomes of Phase II studies and subsequent randomized control studies using identical chemotherapeutic regimens. J. Clin. Oncol. 23, 6982-6991 (2005).
39. Marshall EM, Mendelsohn L, Butler K et al. Treatment of metastatic renal cell carcinoma with coumarin (1,2-benzopyrone) and cimetidine: a pilot study. J. Clin. Cincol. 5, 862-866 (1987).
40. Sagaster P, Micksche M, Flamm J, Ludwig H. Randomised study using IFN-α versus IFN-α plus coumarin'and cimetidine for treatment of advanced renal cell cancer. Ann. Oncol. 6, 999-1003 (1995).
41. Goffin J, Baral S, Tu D et al. Objective responses in patients with malignant melanoma or renal cell cancer in early clinical studies do not predict regulatory approval. Clin. Cancer Res. 11, 5928-5934 (2005).
42. Motzer RJ, Michaelson MD, Rosenberg J et al. Sunitinib efficacy against advanced renal cell cancer. J. Urol. 178, 1883-1887 (2007).
43. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon α, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356, 2271-2281 (2007).
44. Negrier S, Escudier B, Lasset C et al. Recombinant human interleukin-2, recombinant human interferon α-2a, of both in metastatic renal-cell carcinoma. N. Engl. J. Med. 338, 1272-1278 (1998).
45. Tannock I, Murphy K. Reflections on medical oncology: an appeal for better clinical trials and improved reporting of their results. J. Clin. Oncol. 1, 66-70 (1983).
46. Aass N, De Mulder PHM, Mickisch GHJ et al. Randomized Phase II/III trial of interferon α-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell carcinoma (EORTC 30951). J. Clin. Oncol. 23, 4172-4178 (2005).
47. Motzer RJ, Murphy BA, Bacik J et al. Phase III trial of interferon α-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J. Clin. Oncol. 18, 2972-80 (2000).
48. Gordon MS, Manola J, Fairclough D et al. Low dose interferon-a2b + thalidomide in patients with previously untreated renal cell cancer. Improvement in progression-free survival but not quality of life or overall survival. A Phase III study of the Eastern Cooperative Oncology Group (E2898). J. Clin. Oncol. 22(14 Suppl.), A4516 (2004).
49. Law TM, Motzer RJ, Mazumdar M et al. Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer 76, 824-832 (1995).
50. Panelli MC, White R, Foster M et al. Forecasting the cytokine storm following systemic interleukin-2 administration. J. Transl. Med. 2, 17-30 (2004).
51. Siegal JP, Puri RK. Interleukin-2 toxicity. J. Clin. Oncol. 9, 694-704.
52. Fyfe G, Fisher RI, Rosenberg SA et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol. 13, 688-696 (1995).
53. Fyfe GA, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Long term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. J. Clin. Oncol. 14, 2410-2411 (1996).
54. McDermott DF, Atkins MB. Interleukin-2 therapy of metastatic renal cell carcinoma-predictors of response. Semin. Oncol. 33, 583-587 (2006).
55. Jones M, Philip T, Palmer P et al. The impact of interleukin-2 on survival in renal cancer: a multivariate analysis. Cancer Biother. 8, 275-282 (1993).
56. Yang JC, Sherry RM, Steinberg SM et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J. Clin. Oncol. 21, 3127-3132 (2003).
57. McDermott DF, Regan MM, Clark JI et al. Randomized Phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 23, 133-141 (2005).
58. Rosenberg SA, Lotze MT, Yang JC et al. Prospectivc randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J. Natl. Cancer Inst. 85, 622-32 (1993).
59. Jonasch E, Haluska FG. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist 6, 34-55 (2001).
60. Pyrhonen S, Salminen E, Ruutu M et al. Prospective randomized trial of interferon α-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J. Clin. Oncol. 17, 2859-2867 (1999).
61. Neidhart JA, Anderson SA, Harris JE et al. Vinblastine fails to improve response of renal cancer to interferon α-n1: high response rate in patients with pulmonary metastases. J. Clin. Oncol. 9, 832-836 (1991).
62. Fossa SD, Martinelli G, Otto U et al. Recombinant interferon α-2a with or without vinblastine in metastatic renal cell carcinoma: results of a European multicenter Phase III study. Ann. Oncol. 3, 301-305 (1992).
63. Mickisch GHJ. Rational selection of a control arm for randomized trials in metastatic renal cell carcinoma. Eur. Urol. 43, 670-679 (2003).
64. Kirkwood JM, Harris JE, Vera R et al. A randomized study of low and high doses of leukocyte α-interferon in metastatic renal cell carcinoma: the American Cancer Society Collaborative Trial. Cancer Res. 45, 863-871 (1985).
65. Kirkwood JM, Ibrahim, Sosman JA et al. High-dose interferon α-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J. Clin. Oncol. 19, 2370-2380 (2001).
66. Caraceni A, Gangeri L, Martini C et al. Neurotoxicity of interferon-α in melanoma therapy. Cancer 83, 482-489 (1998).
67. Atzpodien J, Kirchner H, Illiger HJ et al. IL-2 in combination with IFN-α and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br. J. Cancer 85, 1130-1136 (2001).
68. Atzpodien J, Kirchner H, Jonas U et al. Inteleukin-2 and interferon α-2a-based immunochemotherapy in advanced renal cell carcinoma: a prospectively randomized trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J. Clin. Oncol. 22, 1188-1194 (2004).
69. Negrier S, Caty A, Lesimple T et al. Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon α with or without fluorouracil. J. Clin. Oncol. 18, 4009-4015 (2000).
70. Negrier S, Perol D, Ravaud A et al. Medroxyprogesterone, interferon α-2a, interleukin-2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis. Cancer 110, 2468-2477 (2007).
71. Flanigan RC, Salmon SE, Blumenstein BA et al. Nephrectomy followed by interferon α-2b compared with interferon α-2b alone for metastatic renal-cell cancer. N. Engl. J. Med. 345, 1655-1659 (2001).
72. Mickisch GHJ, Garin A, van Poppel H et al. Radical nephrectomy plus interferon-α-based immunotherapy compared with interferon α alone in metastatic renal-cell carcinoma: a randomized trial. Lancet 358, 966-970 (2001).
73. Flanigan RC, Nephrectomy for metastatic renal-cell cancer. N. Engl. J. Med. 346, 1095-1096 (2002).
74. Bex A, Kerst M, Mallo H et al. Interferon α2b as medical selection for nephrectomy in patients with synchronous metastatic renal cell carcinoma: a consecutive study. Eur. Urol. 49, 76-81 (2006).
75. Rini BI, Campbell SC. The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy. J. Urol. 177, 1978-1984 (2007).
76. Dutcher JP, Szczylik C, Tannir N et al. Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma receiving temsirolimus or interferon-α. J. Clin. Oncol. 25(18 Suppl.), A5033 (2007).
77. Osband ME, Lavin PT, Babayan RK et al. Effect of autolymphocyte therapy on survival and quality of life in patients with metastatic renal-cell carcinoma. Lancet 335, 994-998 (1990).
78. Dillman RO. Lymphocyte therapy of renal cell carcinoma. Expert Rev. Anticancer Ther. 5, 1041-1051 (2005).
79. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon α in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115-124 (2007).
80. Szczylik C, Demkow T, Staehler M et al. Randomized Phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results. J. Clin. Oncol. 25(18 Suppl.), A5025 (2007).
81. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356, 125-134 (2007).
82. Bukowski R, Cella D, Gondek K, Escudier B. Effects of sorafenib on symptoms and quality of life. Results from a large randomized placebo-controlled study in renal cancer. Am J. Clin. Oncol. 30, 220-227 (2007).
83. Bukowski RM, Eisen T, Szczylik C et al. Final results of the randomized Phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis. J. Clin. Oncol. 25(18 Suppl.), A5023 (2007).
84. Novick AC. Kidney cancer: past, present, and future. Urol. Onc. 25, 188-195 (2007).
85. Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am. J. Surg. Path. 27, 612-624 (2003).
86. Breda A, Knoijeti R, Lam JS. Patterns df recurrence and surveillance strategies for renal cell carcinoma following surgical resection. Expert Rev. Anticancer Ther. 7, 847-862 (2007).
87. Jacobsohn KM, Wood CG. Adjuvant therapy for renal cell carcinoma. Semin. Oncol. 33, 576-582 (2006).
88. Atzpodien J, Schmitt E, Gertenbach U et al. Adjuvant treatment with interleukin-2- and interferon-α2a-based chemoimmunotherapy in renal cell carcinoma post tumor nephrectomy: results of a prospectively randomized trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group. Br. J. Cancer 92, 843-846 (2005).
89. Passalacqua R, Buzio C, Buti S et al. Adjuvant low-dose interleukin-2 plus interferone-α in operable renal cell cancer. A Phase III, randomized, multicenter, independent trial of the Italian Oncology Group for Clinical Research. J. Clin. Oncol. 25(18 Suppl.), LBA5028 (2007).
90. Jocham D, Richter A, Hoffmann L et al. Adjuvant autologous renal tumor cell vaccine and risk of tumor progression in patients with renal-cell carcinoma after radical nephrectomy: Phase III, randomized controlled trial. Lancet 363, 594-599 (2004).
91. Doehn C, Richter A, Theodor RA et al. An adjuvant vaccination with Reniale prolongs survival in patients with renal cell carcinoma following radical nephreectomy: secondary analysis ofa multicenter Phase III trial. Proc. Am. Urol. Assoc. A500 (2007).
92. Wood CG, Escudier B, Lacombe L et al. A multicenter, randomized, Phase III trial of a novel autologous therapeutic vaccine (Vitespen) vs observation as adjuvant therapy in patients at high risk of recurrence after nephrectomy for renal cell carcinoma. Proc. AUA A633 (2007).
93. Eddy D. Principles for making difficult decisions in difficult times. JAMA 271, 1792-1798 (1994).
94. Sipes-Metzler PR. Health care reform in Oregon. Leadership 3, 33-36 (1996).
95. Fricker J. Inequalities in access to renal cancer drugs. Eur. J. Cancer 43, 1225 (2007).
96. Wright JC, Weinstein MC. Gains in life expectancy from medical interventions - standardizing data on outcomes. N. Engl. J. Med. 339, 380-386 (1998).
97. Coppin C. Sunitinib for advanced renal cell cancer. Biologics: targets and therapy 2, 1-9 (2008).
98. Ravaud A. Key considerations in patient selection fort he use of targeted therapy in metastatic renal cell carcinoma. EJC Suppl. 5, 20-27 (2007).
99. Atkins MB, Ernstoff MS, Figlin RA et al. Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference. Clin. Cancer Res. 13, S667-S670 (2007).
100. Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus in interferon α-2a for treatment of metastatic renal cell carcinoma: a randomized, double-blind Phase III trial. Lancet 370, 2103-2111 (2007).
101. Bracarda S, Porta C, Boni C et al. Randomized prospective Phase II trial of two schedules of sorafenib daily and interferon-α2a in metastatic renal cell carcinoma (RAPSODY): GOIRC Study 0681. J. Clin. Oncol. 25(18S), A5100 (2007).
102. Jonasch E, Corn P, Ashe RG, Do K, Tannir NM. Randomized Phase II study of sorafenib with or without low-dose IFN in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 25(18 Suppl.), A5104 (2007).
103. Sternberg C. Novel targeted and signalling pathway inhibitors - ongoing studies. Eur. J. Cancer 5, A37 (2007).
104. Garcia JA, Rini BI, Mekhail T et al. A Phase II trial of low-dose interleukin-2 and bevacizumab in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 25(18 Suppl.), A5103 (2007).
105. Ljungberg B. Prognostic markers in renal cell carcinoma. Curr. Opinion Urol. 17, 303-308 (2007).
106. Upton MP, Parker RA, Youmans A, McDermott DF, Atkins MB. Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. J. Immunother. 28, 488-495 (2005).
107. Atkins M, Regan M, McDermott D et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin. Cancer Res. 11, 3714-3721 (2005).
108. Rini BI, Weinberg V, Dunlap S et al. Maximal COX-2 immunostaining and clinical response to celecoxib and interferon α therapy in metastatic renal cell carcinoma. Cancer 106, 566-575 (2006).
109. Korkola JE, Kondagunta GV, Reuter VE, Motzer RJ, Chaganti RSK. Interferon-α resistance associated genes in renal cell carcinoma identified by expression profiling. J. Urol. 177, 1264-1268 (2007).
110. Ito N, Eto M, Nakamura E et al. STAT3 polymorphism predicts interferon-α response in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 25, 2785-2791 (2007).
111. + regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J. Clin. Oncol. 24, 1169-1177 (2006).
112. Lesinski GB, Kondadasula SV, Crespin T et al. Multiparametric flow cytometric analysis of inter-patient variation in STAT1 phosphorylation following interferon α immunotherapy. J. Natl. Cancer Inst. 96, 1331-1342 (2004).
113. Arico L, Parlato S, Capone I et al. Microarray analysis for monitoring the response to interferon. J. Immunother. 28, 619-620 (2005).
114. Stroncek DF, Burns C, Martin BM. Advancing cancer biotherapy with proteomics. J. Immunother. 28, 183-192 (2005).
115. Gallagher DC, Bhatt RS, Parikh SM et al. Angiopoietin 2 is a potential mediator of high-dose interleukin 2-induced vascular leak. Clin. Cancer Res. 13, 2115-2120 (2007).
116. Yang JC, Topalian SL, Schwartzentruber DJ et al. The use of polyethylene glycol-modified interleukin-2 in the treatment of patients with metastatic renal cell carcinoma and melanoma. Cancer 76, 687-694 (1995).
117. Tagliaferri P, Caraglia M, Budillon A et al. New pharmacokinetic and pharmacodynamic tools for interferon-α treatment of human cancer. Cancer Immunol. Immunother. 54, 1-10 (2005).
118. Childs R, Chernoff A, Contentin N et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N. Engl. J. Med. 343, 750-758 (2000).
119. Ueno NT, Childs RW. What's past is prologue: lessons learned and the need for further development of allogeneic hematopoietic stem cell transplantation for renal cell carcinoma. Biol. BMT 13, 31-33 (2007).
120. Avigan D. Dendritic cell-tumor fusion vaccines for renal cell carcinoma. Clin. Cancer Res. 10, S6347-S6352 (2004).
121. Cao A, Hernandez-McLean J, Willis J et al. Activity of MVA 5T4 alone or in combination with either interleukin-2 or interferon-a in patients with metastatic renal cell cancer. J. Clin. Oncol. 25 (18 Suppl.), A3069 (2007).
122. Yu M, Finn OJ. DNA vaccines for cancer too. Cancer Immunol. Immunother. 55, 119-130 (2006).
123. Kubler H, Vieweg J. Vaccines in renal cell carcinoma. Semin. Oncol. 22, 614-624 (2006).
124. Ernstoff MS, Crocenzi TS, Seigne JD et al. Developing a rational tumor vaccine therapy for renal cell carcinoma: immune yin and yang. Clin. Cancer Res. 13(2S), 733s-740s (2007).
125. Disis ML. Molecular targeting with cancer vaccines. J. Clin. Oncol. 23, 4840-4841 (2005).
126. Kim HL, Sun X, Subjeck JR, Wang X-Y. Evaluation of renal cell carcinoma vaccines targeting carbonic anhydrase IX using heat shock protein 110. Cancer Immunol. Immunother. 56, 1097-1105 (2007).
127. Yang JC, Hughes M, Kammula U et al. Ipilimumab (anti-CTKA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J. Immunother. 30, 825-830 (2007).
128. Kortylewski M, Yu H. Stat3 as a potential target for cancer immunotherapy. J. Immunother. 30, 131-139 (2007).
129. Thompson RH, Dong H, Kwon ED. Implications of B7-H1 expression in clear cell carcinomas of the kidney for prognostication and therapy. Clin. Cancer Res. 13, S709-S715 (2007).
130. Frankenberger B, Noessner E., Schendel DJ. Immune suppression in renal cell carcinoma. Semin. Cancer Biol. 17, 330-343 (2007).